SCHEMBL1764980

SCHEMBL1764980

CCOC(=O)c1cc(-c2cccc(F)c2)n(-c2ccc(F)c(Cl)c2)n1

nearest known ligand 0.53

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.53
CA9 Q16790 2/20 0.52
FAAH O00519 8/20 0.52
MGLL Q99685 3/20 0.52
RPA1 P27694 3/20 0.51
THRB P10828 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1765415 0.91 CHRNA7 (0.64) CHRNA7CA9FAAHMGLLRPA1
SCHEMBL1765031 0.91 CHRNA7 (0.60) CHRNA7CA9FAAHMGLLRPA1
SCHEMBL1765261 0.89 FAAH (0.56) CHRNA7CA9FAAHMGLLRPA1
SCHEMBL1526084 0.89 CHRNA7 (0.54) CHRNA7CA9FAAHMGLLRPA1
SCHEMBL1764943 0.89 FAAH (0.53) CHRNA7CA9FAAHMGLLRPA1
SCHEMBL1765280 0.89 CHRNA7 (0.50) CHRNA7CA9FAAHMGLLRPA1
SCHEMBL1764884 0.88 CHRNA7 (0.53) CHRNA7CA9FAAHMGLLRPA1
SCHEMBL1765306 0.88 CHRNA7 (0.55) CHRNA7CA9FAAHMGLLLMNA
SCHEMBL1764962 0.88 FAAH (0.55) CHRNA7CA9FAAHMGLLRPA1
SCHEMBL1765448 0.87 CHRNA7 (0.67) CHRNA7CA9FAAHMGLLTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
WO-2009115213-A1 (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES AICURIS GMBH & CO. KG (DE) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE TPMT, PAICS, THPO CHRNA7 3365/4885CA9 4825/4885FAAH 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.